CD80 and breast carcinoma: Therefore, we analyzed the presence of CD14+HLA-DRlow/-Co-receptorlow/- (i.e. negative for co-receptors such as CD86 and CD80) Mo-MDSCs in the peripheral blood of breast cancer patients.